JPM European Pharma & Biotech names will present over four days at the J.P. Morgan Healthcare Conference (Jan 12–15, 2026, all times PST), with M&A firepower and BD optionality a core cross‑stock theme. Below is a concise calendar plus key M&A‑relevant angles in a Bloomberg‑style note.
Conference calendar (PST)
Monday, Jan 12
- 07:30 – GSK
- 08:15 – Argenx
- 09:00 – Novartis
- 09:45 – Sanofi
- 11:15 – Merck KGaA
- 13:30 – Galderma
- 14:15 – Oxford Nanopore
- 15:00 – Roche
Tuesday, Jan 13
- 07:30 – GSK (listed under Tuesday in schedule table, but also shown in header as Tuesday presenter; handbook table aligns with GSK at 07:30)
- 09:00 – AstraZeneca
- 09:45 – Novo Nordisk / Sandoz
- 10:30 – Lonza
- 11:15 – Bayer
- 13:30 – Zealand
- 15:45 – Genmab
- 16:30 – Ipsen
Wednesday, Jan 14
- 07:30 – UCB
- 11:15 – Recordati
- 13:30 – Zealand (as per main schedule table)
- 15:00 – Bachem
Thursday, Jan 15
- 10:30 – Molecular Partners
(Grifols has no conference presentation; Oxbio and various small caps are covered in the handbook but not in the core EU pharma schedule table.)
Cross‑sector M&A setup
- Large‑cap firepower remains substantial: JPM estimates EU large caps have sizeable deal capacity at 3.0x 2025E Net Debt/EBITDA, led by Roche, Novartis, Novo, Sanofi, Bayer and Merck, reinforcing scope for structured BD and bolt‑ons rather than mega‑mergers.
- Post‑2030 patent cliff drives external growth: Report explicitly flags “firepower” as increasingly important as EU large caps look beyond 2030, keeping M&A and in‑licensing at the centre of equity stories into and beyond JPM week.
Name‑by‑name M&A / BD angles
Novartis (Mon 09:00)
- Balance sheet and firepower charts place Novartis among the group with significant headroom at ~3x 2025E Net Debt/EBITDA, underpinning continued BD optionality.
- Pipeline grid highlights multiple late‑stage assets (pelacarsen, zigakibart, del‑desiran, abelacimab, del‑zota, del‑brax), tilting strategy toward targeted bolt‑on deals and licensing to complement in‑house programs rather than transformational M&A.
Sanofi (Mon 09:45)
- Sector section emphasises the need to supplement organic amlitelimab and immunology build‑out with externally sourced assets as Sanofi manages high‑single‑digit EPS ambitions and FX headwinds.
- AATD and immunology readouts plus continued focus on specialty care keep Sanofi positioned as both a buyer (immunology, rare disease) and occasional partner of choice.
Merck KGaA (Mon 11:15)
- JPM explicitly flags potential “corporate” moves including a partnership announcement for precemtabart tocentecan (M9140) and “potential M&A / business development in Life Sciences.”
- Disposal of Surface Solutions and acquisition of SpringWorks reshape the portfolio; 2026 guidance discussion links FX and BD to EBITDA trajectory, signalling ongoing portfolio reshuffling rather than scale M&A.
Roche (Mon 15:00)
- High absolute firepower and relatively moderate leverage (Net Debt/EBITDA) place Roche at the top end of EU large‑cap deal capacity.JPM_European_Pharma-Conference-Book-1.pdf
- Obesity, neurology and hematology assets (petrelintide, CT‑996, CT‑388, Evrysdi combinations) are highlighted as pipeline pillars, with external innovation likely to remain a lever to sustain growth vs. consensus.JPM_European_Pharma-Conference-Book-1.pdf
GSK (Tue 07:30)
- Guidance narrative focuses on managing U.S. vaccine pricing headwinds and investing into oncology and respiratory; M&A frame is more selective, with emphasis on targeted assets rather than large scale deals.JPM_European_Pharma-Conference-Book-1.pdf
- Newsflow list includes a potential Capital Markets Day for the new CEO strategy in 3Q26, where M&A / BD framework will likely be a key topic.
AstraZeneca (Tue 09:00)
- Strong 2025‑30 growth profile but still reliant on external innovation in oncology and rare disease; multiple pivotal datasets (Dato‑DXd, AZD0901, camizestrant, eplontersen) reduce urgency for large M&A but support bolt‑on appetite using balance‑sheet headroom.
- Cardiometabolic and obesity adjacency (Eplontersen, etc.) positions AZN as a logical future consolidator in cardiometabolic and genetic disease platforms.
Novo Nordisk (Tue 09:45)
- Obesity and diabetes cash flows underpin significant theoretical deal capacity, but handbook stresses focus on internal obesity pipeline (CagriSema, Amycretin, ziltivkemab) and competitive dynamics vs. Lilly rather than large M&A.
- BD read‑through is more about tuck‑ins or technology deals that extend GLP‑1/GIP/tri‑agonist leadership.
Bayer (Tue 11:15)
- One of the larger firepower contributors, but litigation overhang (glyphosate, dicamba) constrains near‑term big‑ticket M&A.
- JPM frames Bayer as a positive catalyst watch into asundexian OCEANIC‑Stroke data and multiple litigation milestones, implying any sizeable M&A is more a medium‑term option once legal visibility improves.
Lonza (Tue 10:30)
- Mid‑cap CDMO strongly positioned as a target of pharma outsourcing wallets; JPM highlights CDMO‑driven growth with margin expansion and specific 2026 newsflow around Vacaville contracting and CHI divestment.
- Strategic narrative is about portfolio optimisation (divest CHI, add capacity/tech via smaller deals) rather than selling the group or pursuing large acquisitions.
Galderma (Tue 13:30)
- Aesthetics and dermatology growth plus Ipsen arbitration around a terminated early‑stage R&D collaboration underscore BD intensity in the space.
- Guidance assumptions include continued investment in commercial and R&D, suggesting scope for further bolt‑on brand/asset deals while keeping leverage in check.
Genmab (Tue 15:45)
- Heavy reliance on partnered programs (Darzalex, Kesimpta, Epkinly) positions Genmab structurally as a BD platform story, but JPM’s cuts to 2026 EPS vs. consensus underscore the execution risk.
- 2026‑27 data (Epkinly 1L DLBCL, petosemtamab) could be triggers for broader strategic interest from large caps seeking antibody / bispecific know‑how.
Ipsen (Tue 16:30)
- Ipsen explicitly flagged with potential 2026 “M&A to add to the pipeline,” alongside a potential update on the Galderma arbitration.
- With expected 2026 core margin at ~30% and growth skewed to specialty, Ipsen screens both as an acquirer of late‑stage specialty assets and as a mid‑cap consolidation candidate.
UCB (Wed 07:30)
- Catalyst watch name with firepower focused on immunology and neurology; handbook emphasises 2025‑30 EPS CAGR and need to keep replenishing the portfolio.
- Donzakimig, Rystiggo and Bimzelx data frame UCB more as a bolt‑on acquirer / licensing player than a large take‑out target in the near term.
Recordati (Wed 11:15)
- Explicit “potential further M&A / BD update on CVC stake” flagged in 2026 newsflow, putting capital allocation and deal appetite on the agenda.
- Expected revenue and EBITDA ranges for 2026 leave room for targeted rare‑disease or specialty additions, consistent with its historical BD footprint.
Zealand (Wed 13:30)
- Obesity pipeline (petrelintide, survodutide, CT‑388) dominates NPV and is co‑developed with a partner, making Zealand a structurally strategic mid‑cap in the obesity M&A theme.
- JPM models large royalty streams and partnership economics, implicitly positioning the name as both a partner and a potential take‑out once Phase II/III risk clears.
Bachem (Wed 15:00)
- Peptide / oligo CDMO with strong growth; 2026 newsflow items include new CEO strategy and continued emphasis on investments and contracts in GLP‑1 and peptide supply.
- Strategically, Bachem sits in the “scarce assets” bucket for large‑cap buyers wanting secure GLP‑1/API supply, even if JPM does not explicitly flag live M&A.
Oxford Nanopore (Mon 14:15)
- 2026 commentary highlights likely trading update at JPM and FY25 guidance, with emphasis on ONT and peer commentary; no explicit M&A flag, but technology remains highly strategic for genomics players.
Molecular Partners (Thu 10:30)
- Handbook very explicit on partnering strategy: MP0533 in AML is expected to be out‑licensed if Phase I data are positive, with modelled 500m peak sales and 20% royalties.
- MP0712 (DLL3 radio‑DARPin) and MP0726 (MSLN radio‑DARPin) are positioned for BD (partnering milestones, royalties), making JPM framing clearly “platform for out‑licensing” rather than stand‑alone fully integrated biotech.
How to trade the M&A angle into JPM
- Buy firepower + need: Roche, Novartis, Sanofi, Bayer, Merck and AZN screen as best‑placed to deploy balance sheets against mid‑cap and platform stories; JPM firepower charts support this view.JPM_European_Pharma-Conference-Book-1.pdf
- Key “assets for sale” narratives: Lonza, Bachem, Zealand, Oxford Nanopore and Molecular Partners are portrayed as structurally positioned to monetise technology via partnerships or, longer term, strategic interest from larger buyers.
